Viral infections in mice with reconstituted human immune system components

Immunology Letters

Volumn 161, Issue 1, 2014, Pages 118-124

  Münz, Christian ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Dengue virus; EBV; HIV; NK cells; T cells

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD34 ANTIGEN; CD4 ANTIGEN; IMMUNOLOGIC FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; RECONSTITUTED HUMAN IMMUNE SYSTEM COMPONENT; UNCLASSIFIED DRUG;

ADENOVIRUS INFECTION; ANTIGEN RECOGNITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; DENGUE; DISEASE MODEL; DNA VIRUS INFECTION; EPSTEIN BARR VIRUS INFECTION; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNE SYSTEM COMPONENT RECONSTITUTION MOUSE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INFLUENZA A; JC VIRUS; KAPOSI SARCOMA; MOUSE; MOUSE STRAIN; NONHUMAN; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; RNA VIRUS INFECTION; T CELL DEPLETION; TROPISM; VIRUS INFECTION; VIRUS LOAD; ANIMAL; GENETICS; HOST PATHOGEN INTERACTION; IMMUNE SYSTEM; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC SURVEILLANCE; MICE; VIRUS DISEASES;

EID: 84902479310     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.05.012     Document Type: Review

References (89)

1. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172:2731-2738.
2. Waterston R.H., Lindblad-Toh K., Birney E., Rogers J., Abril J.F., Agarwal P., et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002, 420:520-562.
3. Seok J., Warren H.S., Cuenca A.G., Mindrinos M.N., Baker H.V., Xu W., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013, 110:3507-3512.
4. Legrand N., Weijer K., Spits H. Experimental models to study development and function of the human immune system in vivo. J Immunol 2006, 176:2053-2058.
5. Rongvaux A., Takizawa H., Strowig T., Willinger T., Eynon E.E., Flavell R.A., et al. Human hemato-lymphoid system mice: current use and future potential for medicine. Annu Rev Immunol 2013, 31:635-674.
6. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat Rev Immunol 2007, 7:118-130.
7. Rämer P.C., Chijioke O., Meixlsperger S., Leung C.S., Münz C. Mice with human immune system components as in vivo models for infections with human pathogens. Immunol Cell Biol 2011, 89:408-416.
8. Melkus M.W., Estes J.D., Padgett-Thomas A., Gatlin J., Denton P.W., Othieno F.A., et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 2006, 12:1316-1322.
9. Nochi T., Denton P.W., Wahl A., Garcia J.V. Cryptopatches are essential for the development of human GALT. Cell Rep 2013, 3:1874-1884.
10. -/- mice improves engraftment of human hematopoietic cells in humanized mice. Proc Natl Acad Sci U S A 2011, 108:13218-13223.
11. Legrand N., Huntington N.D., Nagasawa M., Bakker A.Q., Schotte R., Strick-Marchand H., et al. Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer-(NK) cell homeostasis in vivo. Proc Natl Acad Sci U S A 2011, 108:13224-13229.
12. Takenaka K., Prasolava T.K., Wang J.C., Mortin-Toth S.M., Khalouei S., Gan O.I., et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 2007, 8:1313-1323.
13. Rongvaux A., Willinger T., Martinek J., Strowig T., Gearty S.V., Teichmann L.L., et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 2014, 32:364-372.
14. Ehlers B., Dural G., Yasmum N., Lembo T., de Thoisy B., Ryser-Degiorgis M.P., et al. Novel mammalian herpesviruses and lineages within the Gammaherpesvirinae: cospeciation and interspecies transfer. J Virol 2008, 82:3509-3516.
15. Ehlers B., Spiess K., Leendertz F., Peeters M., Boesch C., Gatherer D., et al. Lymphocryptovirus phylogeny and the origins of Epstein-Barr virus. J Gen Virol 2010, 91:630-642.
16. Kwant-Mitchell A., Ashkar A.A., Rosenthal K.L. Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model. J Virol 2009, 83:10664-10676.
17. Smith M.S., Goldman D.C., Bailey A.S., Pfaffle D.L., Kreklywich C.N., Spencer D.B., et al. Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model. Cell Host Microbe 2010, 8:284-291.
18. Hakki M., Goldman D.C., Streblow D.N., Hamlin K.L., Krekylwich C.N., Fleming W.H., et al. HCMV infection of humanized mice after transplantation of G-CSF-mobilized peripheral blood stem cells from HCMV-seropositive donors. Biol Blood Marrow Transplant 2014, 20:132-135.
19. Leung C., Chijioke O., Gujer C., Chatterjee B., Antsiferova O., Landtwing V., et al. Infectious diseases in humanized mice. Eur J Immunol 2013, 43:2246-2254.
20. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J.C., Lanzavecchia A., et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004, 304:104-107.
21. Rickinson A.B., Long H.M., Palendira U., Münz C., Hislop A. Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory. Trends Immunol 2014, 35(4):159-169.
22. Babcock J.G., Hochberg D., Thorley-Lawson A.D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000, 13:497-506.
23. Thorley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001, 1:75-82.
24. Babcock G.J., Decker L.L., Volk M., Thorley-Lawson D.A. EBV persistence in memory B cells in vivo. Immunity 1998, 9:395-404.
25. Laichalk L.L., Thorley-Lawson D.A. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 2005, 79:1296-1307.
26. Strowig T., Gurer C., Ploss A., Liu Y.F., Arrey F., Sashihara J., et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med 2009, 206:1423-1434.
27. Chijioke O., Muller A., Feederle R., Barros M.H., Krieg C., Emmel V., et al. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Rep 2013, 5:1489-1498.
28. White R.E., Rämer P.C., Naresh K.N., Meixlsperger S., Pinaud L., Rooney C., et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 2012, 122:1487-1502.
29. Tsai M.H., Raykova A., Klinke O., Bernhardt K., Gartner K., Leung C.S., et al. Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas. Cell Rep 2013, 5:458-470.
30. -/- mice as a model for Epstein-Barr virus infection. Am J Pathol 2008, 173:1369-1378.
31. Ma S.D., Hegde S., Young K.H., Sullivan R., Rajesh D., Zhou Y., et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 2011, 85:165-177.
32. + cells with Epstein-Barr virus. J Virol 2004, 78:13891-13900.
33. + T cell recognition. J Immunol 2009, 182:1919-1928.
34. Heuts F., Rottenberg M.E., Salamon D., Rasul E., Adori M., Klein G., et al. T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice. J Virol 2014, 88:3235-3245.
35. Sato K., Misawa N., Nie C., Satou Y., Iwakiri D., Matsuoka M., et al. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood 2011, 117:5663-5673.
36. Kuwana Y., Takei M., Yajima M., Imadome K., Inomata H., Shiozaki M., et al. Epstein-Barr virus induces erosive arthritis in humanized mice. PLoS ONE 2011, 6:e26630.
37. Cesarman E. Gammaherpesviruses and lymphoproliferative disorders. Annu Rev Pathol 2014, 9:349-372.
38. Parsons C.H., Adang L.A., Overdevest J., O'Connor C.M., Taylor J.R., Camerini D., et al. KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice. J Clin Invest 2006, 116:1963-1973.
39. Wang L.X., Kang G., Kumar P., Lu W., Li Y., Zhou Y., et al. Humanized-BLT mouse model of Kaposi's sarcoma-associated herpesvirus infection. Proc Natl Acad Sci U S A 2014, 111:3146-3151.
40. Billerbeck E., Horwitz J.A., Labitt R.N., Donovan B.M., Vega K., Budell W.C., et al. Characterization of human antiviral adaptive immune responses during hepatotropic virus infection in HLA-transgenic human immune system mice. J Immunol 2013, 191:1753-1764.
41. Bility M.T., Cheng L., Zhang Z., Luan Y., Li F., Chi L., et al. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog 2014, 10:e1004032.
42. Tager A.M., Pensiero M., Allen T.M. Recent advances in humanized mice: accelerating the development of an HIV vaccine. J Infect Dis 2013, 208(Suppl. 2):S121-S124.
43. -/- mice. Proc Natl Acad Sci U S A 2006, 103:15951-15956.
44. -/- (RAG-hu) mouse model. Retrovirology 2006, 3:76.
45. + T cell depletion in humanized mice infected with HIV-1. J Exp Med 2007, 204:705-714.
46. Murooka T.T., Deruaz M., Marangoni F., Vrbanac V.D., Seung E., von Andrian U.H., et al. HIV-infected T cells are migratory vehicles for viral dissemination. Nature 2012, 490:283-287.
47. Klein F., Halper-Stromberg A., Horwitz J.A., Gruell H., Scheid J.F., Bournazos S., et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492:118-122.
48. Marsden M.D., Kovochich M., Suree N., Shimizu S., Mehta R., Cortado R., et al. HIV latency in the humanized BLT mouse. J Virol 2012, 86:339-347.
49. Denton P.W., Olesen R., Choudhary S.K., Archin N.M., Wahl A., Swanson M.D., et al. Generation of HIV latency in humanized BLT mice. J Virol 2012, 86:630-634.
50. -/- mouse. J Virol 2012, 86:114-120.
51. Denton P.W., Estes J.D., Sun Z.F., Othieno F.A., Wei B.D.L., Wege A.K., et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008, 5:79-89.
52. Nischang M., Sutmuller R., Gers-Huber G., Audige A., Li D., Rochat M.A., et al. Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting antiretroviral drugs for treating HIV-1. PLoS ONE 2012, 7.
53. Chateau M.L., Denton P.W., Swanson M.D., McGowan I., Garcia J.V. Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice. PLoS ONE 2013, 8:e60024.
54. Kumar P., Ban H.S., Kim S.S., Wu H.Q., Pearson T., Greiner D.L., et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008, 134:577-586.
55. Wheeler L.A., Vrbanac V., Trifonova R., Brehm M.A., Gilboa-Geffen A., Tanno S., et al. Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol Ther 2013, 21(7):1378-1389.
56. + T cells from HIV-1 infection. Blood 2014, 123:61-69.
57. Denton P.W., Long J.M., Wietgrefe S.W., Sykes C., Spagnuolo R.A., Snyder O.D., et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog 2014, 10:e1003872.
58. Balazs A.B., Ouyang Y., Hong C.M., Chen J., Nguyen S.M., Rao D.S., et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 2014, 20:296-300.
59. Banerjee P., Tripp A., Lairmore M.D., Crawford L., Sieburg M., Ramos J.C., et al. Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice. Blood 2010, 115:2640-2648.
60. -/- mice. PLoS Pathog 2011, 7:e1002231.
61. Tezuka K., Xun R., Tei M., Ueno T., Tanaka M., Takenouchi N., et al. An animal model of adult T-cell leukemia: humanized mice with HTLV-1-specific immunity. Blood 2014, 123:346-355.
62. Jaiswal S., Pazoles P., Woda M., Shultz L.D., Greiner D.L., Brehm M.A., et al. Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology 2012, 136:334-343.
63. Jaiswal S., Pearson T., Friberg H., Shultz L.D., Greiner D.L., Rothman A.L., et al. Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice. PLoS ONE 2009, 4:e7251.
64. -/- (RAG-hu) mice. Virology 2007, 369:143-152.
65. Sridharan A., Chen Q., Tang K.F., Ooi E.E., Hibberd M.L., Chen J. Inhibition of megakaryocyte development in the bone marrow underlies dengue virus-induced thrombocytopenia in humanized mice. J Virol 2013, 87:11648-11658.
66. Frias-Staheli N., Dorner M., Marukian S., Billerbeck E., Labitt R.N., Rice C.M., et al. Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing. J Virol 2014, 88:2205-2218.
67. Messina J.P., Brady O.J., Scott T.W., Zou C., Pigott D.M., Duda K.A., et al. Global spread of dengue virus types: mapping the 70 year history. Trends Microbiol 2014, 22:138-146.
68. Bility M.T., Zhang L., Washburn M.L., Curtis T.A., Kovalev G.I., Su L. Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis. Nat Protoc 2012, 7:1608-1617.
69. Washburn M.L., Bility M.T., Zhang L., Kovalev G.I., Buntzman A., Frelinger J.A., et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011, 140:1334-1344.
70. Chalkias S., Dang X., Bord E., Stein M.C., Kinkel R.P., Sloane J.A., et al. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol 2014, [Epub ahead of print].
71. Tan C.S., Broge T.A., Seung E., Vrbanac V., Viscidi R., Gordon J., et al. Detection of JC virus-specific immune responses in a novel humanized mouse model. PLoS ONE 2013, 8:e64313.
72. + mucosal effector T cells via the cytokine TGF-beta. Immunity 2013, 38:818-830.
73. Willinger T., Rongvaux A., Takizawa H., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., et al. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc Natl Acad Sci U S A 2011, 108:2390-2395.
74. -/- mice: functional inactivation of p53 in developing T cells. Blood 2004, 104:3886-3893.
75. Salguero G., Daenthanasanmak A., Münz C., Raykova A., Guzman C.A., Riese P., et al. Dendritic cell-mediated immune humanization of mice: implications for allogeneic and xenogeneic stem cell transplantation. J Immunol 2014, 192(10):4636-4647.
76. Strowig T., Chijioke O., Carrega P., Arrey F., Meixlsperger S., Rämer P.C., et al. Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood 2010, 116:4158-4167.
77. Yajima M., Imadome K., Nakagawa A., Watanabe S., Terashima K., Nakamura H., et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis 2008, 198:673-682.
78. Brainard D.M., Seung E., Frahm N., Cariappa A., Bailey C.C., Hart W.K., et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol 2009, 83:7305-7321.
79. + dendritic cells produce prominent amounts of IFN-alpha after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 2013, 121:5034-5044.
80. Manz M.G. Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity 2007, 26:537-541.
81. + dendritic cells in vivo. J Immunol 2014, 192:1982-1989.
82. Shultz L.D., Saito Y., Najima Y., Tanaka S., Ochi T., Tomizawa M., et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci U S A 2010, 107:13022-13027.
83. + T cell responses in humanized BLT mice. Sci Transl Med 2012, 4.
84. + T cells in HLA-B*51:01 transgenic humanized mice after infection with HIV-1. PLoS ONE 2012, 7.
85. Yajima M., Imadome K., Nakagawa A., Watanabe S., Terashima K., Nakamura H., et al. T cell-mediated control of Epstein-Barr virus infection in humanized mice. J Infect Dis 2009, 200:1611-1615.
86. + cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol 2010, 184:7082-7091.
87. Sanchez Alvarado A., Yamanaka S. Rethinking differentiation: stem cells, regeneration, and plasticity. Cell 2014, 157:110-119.
88. + T cells in vivo. PLoS Pathog 2013, 9:e1003812.
89. Chatterjee B., Leung C.S., Münz C. Animal models of Epstein-Barr virus infection. J Immunol Methods 2014, [Epub ahead of print].